Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Public ClinicalTrials.gov record NCT01020006. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Study identification
- NCT ID
- NCT01020006
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Enrollment
- 42 participants
Conditions and interventions
Interventions
- PCI-27483 Drug
- Gemcitabine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2009
- Primary completion
- Jul 31, 2012
- Completion
- Not listed
- Last update posted
- Apr 23, 2014
Started 2009
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| TGen Clinical Reserch Services at Scottsdale Healthcare | Scottsdale | Arizona | 85258 | — |
| Pacific Cancer Medical Center | Anaheim | California | 92081 | — |
| Space Coast Medical Associates | Titusville | Florida | 32796 | — |
| Investigative Clinical Research of Indiana | Indianapolis | Indiana | 46260 | — |
| Kenthucky Cancer Clinic | Hazard | Kentucky | 41701 | — |
| Park Nicollet Institute | Saint Louis Park | Minnesota | 55426 | — |
| Beth Israel Cancer Center | New York | New York | 10003 | — |
| Columbia University | New York | New York | 10032 | — |
| University of Rochester | Rochester | New York | 14642 | — |
| Summa Health System | Akron | Ohio | 44304 | — |
| Gabrail Cancer Center Research | Canton | Ohio | 44718 | — |
| Gettysburg Cancer Center | Gettysburg | Pennsylvania | 17325 | — |
| Charleston Hematology Oncology Associates | Charleston | South Carolina | 29414 | — |
| South Carolina Cancer Specialists, PA | Hilton Head | South Carolina | 29926 | — |
| Associates in Oncology and Hematology | Chattanooga | Tennessee | 37404 | — |
| Sammons Cancer Center | Dallas | Texas | 75246 | — |
| University of Vermont/Vermont Cancer Center | Burlington | Vermont | 05401 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01020006, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 23, 2014 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01020006 live on ClinicalTrials.gov.